TransMedics Group (NASDAQ:TMDX) Receives "Hold" Rating from Needham & Company LLC

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "hold" rating reissued by stock analysts at Needham & Company LLC in a report released on Wednesday,Benzinga reports.

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Stock Up 4.0 %

Shares of NASDAQ:TMDX opened at $91.21 on Wednesday. The stock has a market capitalization of $3.09 billion, a P/E ratio of 97.03 and a beta of 2.14. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock's 50-day moving average price is $73.24 and its 200-day moving average price is $78.72.

Institutional Investors Weigh In On TransMedics Group

Hedge funds have recently made changes to their positions in the company. Valmark Advisers Inc. boosted its holdings in shares of TransMedics Group by 4.5% during the 1st quarter. Valmark Advisers Inc. now owns 7,213 shares of the company's stock valued at $485,000 after buying an additional 309 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in TransMedics Group by 23.0% during the first quarter. Oppenheimer & Co. Inc. now owns 78,002 shares of the company's stock worth $5,248,000 after acquiring an additional 14,578 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in TransMedics Group by 65.9% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,692 shares of the company's stock worth $787,000 after purchasing an additional 4,643 shares during the period. Abundance Wealth Counselors grew its holdings in TransMedics Group by 22.0% in the first quarter. Abundance Wealth Counselors now owns 6,747 shares of the company's stock worth $454,000 after purchasing an additional 1,218 shares during the period. Finally, Cornerstone Wealth Management LLC increased its stake in shares of TransMedics Group by 68.5% during the first quarter. Cornerstone Wealth Management LLC now owns 6,247 shares of the company's stock valued at $420,000 after purchasing an additional 2,540 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.